Welcome to our dedicated page for RESPIRERX PHARMA news (Ticker: RSPI), a resource for investors and traders seeking the latest updates and insights on RESPIRERX PHARMA stock.
RESPIRERX PHARMA INC (RSPI) is a pharmaceutical company focused on developing innovative treatments for various respiratory disorders and neurological conditions. The company's core business revolves around the research and development of therapeutic solutions that target specific neurotransmitter pathways to address unmet medical needs.
RESPIRERX PHARMA INC has recently made significant strides in advancing its lead product candidates, including ResolutionRx, a novel pharmaceutical cannabinoid being developed to treat respiratory conditions, and EndeavourRx, a cutting-edge neuromodulator designed to address neurological disorders. The company's financial condition remains robust, supported by strategic partnerships and a pipeline of promising products in various stages of development.
RespireRx Pharmaceuticals announced a $1.8 million award from the Department of Defense (DOD) to fund Phase 2 clinical trials for CX1739, their lead AMPAkine, aimed at improving bladder function in patients with spinal cord injury (SCI). Conducted by Shirley Ryan AbilityLab and led by Dr. Milap Sandhu, the study will have two stages: Phase 2A for single dose safety and efficacy, and Phase 2B for placebo-controlled trials. RespireRx has been allocated $252,200 for manufacturing and regulatory submissions. Clinical trials are projected to begin by Q4 2024. CX1739 has previously shown promising results in preclinical animal studies and early human trials.
RespireRx Pharmaceuticals Inc. (OTC Markets: RSPI) has entered a material transfer agreement with University College London (UCL) to collaborate on research involving CX1739, its lead AMPAkine, aimed at treating GRIA disorders. These rare genetic diseases affect AMPA receptor functioning, impacting learning and memory. Dr. Ian Coombs is leading efforts to identify specific genetic variants in children with GRIA Disorder to tailor treatments effectively. Positive effects of CX1739 have been noted in animal models, and the study seeks to confirm its therapeutic potential in humans.